Precision BioSciences (DTIL) Competitors $5.02 +0.01 (+0.20%) Closing price 04:00 PM EasternExtended Trading$5.03 +0.01 (+0.20%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. ACTU, LYEL, GLSI, IKT, PRQR, FDMT, NMRA, LRMR, NGNE, and SCPHShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Actuate Therapeutics (ACTU), Lyell Immunopharma (LYEL), Greenwich LifeSciences (GLSI), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), Larimar Therapeutics (LRMR), Neurogene (NGNE), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Actuate Therapeutics Lyell Immunopharma Greenwich LifeSciences Inhibikase Therapeutics ProQR Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Larimar Therapeutics Neurogene scPharmaceuticals Actuate Therapeutics (NASDAQ:ACTU) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation. Does the MarketBeat Community believe in ACTU or DTIL? Precision BioSciences received 94 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 68.84% of users gave Precision BioSciences an outperform vote. CompanyUnderperformOutperformActuate TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesPrecision BioSciencesOutperform Votes9568.84% Underperform Votes4331.16% Do analysts prefer ACTU or DTIL? Actuate Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 150.00%. Precision BioSciences has a consensus target price of $37.67, suggesting a potential upside of 650.33%. Given Precision BioSciences' higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in ACTU or DTIL? 38.0% of Precision BioSciences shares are owned by institutional investors. 4.0% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is ACTU or DTIL more profitable? Precision BioSciences has a net margin of 11.48% compared to Actuate Therapeutics' net margin of 0.00%. Actuate Therapeutics' return on equity of 0.00% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Precision BioSciences 11.48%-23.69%-6.98% Which has stronger valuation & earnings, ACTU or DTIL? Actuate Therapeutics has higher earnings, but lower revenue than Precision BioSciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/APrecision BioSciences$68.70M0.77-$61.32M$1.902.64 Does the media refer more to ACTU or DTIL? In the previous week, Precision BioSciences had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for Precision BioSciences and 2 mentions for Actuate Therapeutics. Precision BioSciences' average media sentiment score of 0.00 beat Actuate Therapeutics' score of -0.62 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPrecision BioSciences beats Actuate Therapeutics on 9 of the 13 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.62M$2.84B$5.29B$7.35BDividend YieldN/A1.90%5.12%4.31%P/E Ratio83.6830.4821.7117.77Price / Sales0.77441.91379.3997.68Price / CashN/A168.6838.2234.64Price / Book1.113.466.443.98Net Income-$61.32M-$72.06M$3.21B$247.44M7 Day Performance18.68%6.38%5.24%4.44%1 Month Performance-0.59%-17.51%-9.49%-7.73%1 Year Performance-56.39%-27.84%11.01%1.28% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences3.536 of 5 stars$5.02+0.2%$37.67+650.3%-61.1%$52.62M$68.70M83.68200Short Interest ↑News CoverageACTUActuate TherapeuticsN/A$6.82-1.0%$20.00+193.3%N/A$133.21MN/A0.0010News CoverageLYELLyell Immunopharma3.184 of 5 stars$0.45-3.9%$1.00+123.9%-81.8%$131.85M$61,000.00-0.57270Analyst ForecastNews CoverageGap DownGLSIGreenwich LifeSciences1.952 of 5 stars$9.59+8.6%$38.00+296.2%-38.7%$126.06MN/A-11.993Earnings ReportUpcoming EarningsGap DownHigh Trading VolumeIKTInhibikase Therapeutics1.4399 of 5 stars$1.68-8.7%$6.50+286.9%-8.3%$124.90M$260,000.00-0.636News CoveragePRQRProQR Therapeutics2.1859 of 5 stars$1.17-0.8%$9.50+712.0%-43.0%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.5761 of 5 stars$2.65-4.3%$26.71+908.1%-89.1%$122.70M$37,000.00-0.93120Analyst RevisionNMRANeumora Therapeutics3.1624 of 5 stars$0.75+2.3%$9.29+1,132.8%-94.3%$122.00MN/A-0.40108Gap DownLRMRLarimar Therapeutics3.2936 of 5 stars$1.87-4.6%$19.63+949.5%-74.6%$119.73MN/A-1.6330Positive NewsNGNENeurogene2.1318 of 5 stars$7.86-10.6%$53.00+574.3%-69.4%$117.35M$925,000.00-1.8490Analyst ForecastGap DownHigh Trading VolumeSCPHscPharmaceuticals3.7375 of 5 stars$2.33+0.4%$14.00+500.9%-45.4%$117.16M$36.33M-1.2330Short Interest ↓Gap Down Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Lyell Immunopharma Alternatives Greenwich LifeSciences Alternatives Inhibikase Therapeutics Alternatives ProQR Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Neumora Therapeutics Alternatives Larimar Therapeutics Alternatives Neurogene Alternatives scPharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
